NCT04260295|UnknownDMC
Study of the Correlation of Tumor Tissue Microbiome to the Pathogenesis of Lung Cancer
STARS
A Cross-sectional Study of the Correlation of Tumor Tissue Microbiome to the Pathogenesis of Lung Cancer
Loading search results
STARS
A Cross-sectional Study of the Correlation of Tumor Tissue Microbiome to the Pathogenesis of Lung Cancer
Sponsor study identifier
observational
300
1 country
1
Study Start
November 1, 2019
Actual (reported)Primary Completion
July 31, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 31, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Lung cancer is the malignant tumor with the highest incidence, accounting for the first cause of tumor death. At present, smoking, occupational and environmental exposure, air pollution and genetic factors are considered to be related to the incidence of lung cancer. However, the occurrence of cancer is related to many factors. In recent years, researches have found that microorganisms are closely related to various human cancers. It is reported that 20% of cancers are related to multiple microorganisms, such as EB virus and nasopharyngeal cancer, HBV and liver cancer. Understanding the correlation between pathogenic microorganisms and cancer is of great significance for the pathogenesis, prevention and treatment of cancer. Basic researches have found that mycotoxins are related to animal models of lung cancer, but have not been confirmed in clinical and human. With the help of microbial metagenome Next Generation Sequencing (mNGS) and bioinformatics analysis, the investigators initially found in clinical practice that some patients had fungal infections such as fungi in lung cancer tissues. This study intends to collect clinical cases (cross-sectional studies) to explore the correlation between the pathogenic microbiome and lung cancer, in order to confirm that the occurrence of lung cancer is closely related to microorganisms such as fungi.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 31, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 1, 2019
Actual (reported)February 5, 2020
Actual (reported)February 7, 2020
Actual (reported)July 31, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
July 31, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Number of cases of fungi found in lung cancer tissues
Number of cases of fungi found in lung cancer tissues by pathology and next-generation sequencing of microorganisms
21 months
Number of cases of fungi found in non-lung cancer tissues
Number of cases of fungi found in non-lung cancer tissues by pathology and next-generation sequencing of microorganisms
21 months
Number of cases of microorganisms found in lung cancer tissue
21 months
Number of cases of microorganisms found in non-lung cancer tissue
21 months
The subjects of this study are patients with lung shadow confirmed by CT-guided percutaneous lung biopsy. They mainly include infectious diseases of the lung, Tumors and interstitial lung diseases. The subjects are patients who cannot be diagnosed by conventional non-invasive testing methods (including blood, sputum and other specimens) and bronchoscopy, and the patients need to be diagnosed and treated as soon as possible (such as lung tumors, lung infections and other diseases ).
Huashan hospital,Fudan university
Shanghai, Shanghai Municipality, 200040, China
Obtaining pathological and etiology of lung lesion tissue for examination is a necessary and effective diagnostic measure. Part of the biopsy tissue will be submitted for pathology and immunohistochemical detection, and the other part will be submitted for microbial mNGS detection.
Shengqing Li, PhD
Huashan Hospital
First Submitted
February 5, 2020
First Posted
February 7, 2020
Study Start
November 1, 2019
Actual (reported)Primary Completion
July 31, 2021
Estimated (date passed)Early Cancer Detection Test - Lung Cancer China
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 31, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
February 7, 2020
Record last verified: 2020-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: